Cyclin-Dependent Kinase Inhibitor p57
"Cyclin-Dependent Kinase Inhibitor p57" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent inhibitor of CYCLIN-DEPENDENT KINASES in G1 PHASE and S PHASE. In humans, aberrant expression of p57 is associated with various NEOPLASMS as well as with BECKWITH-WIEDEMANN SYNDROME.
| Descriptor ID |
D050761
|
| MeSH Number(s) |
D12.644.360.225.700 D12.776.167.187.700 D12.776.476.225.700 D12.776.624.776.355.700
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p57- Cyclin-Dependent Kinase Inhibitor p57
- Cyclin Dependent Kinase Inhibitor p57
- p57 KIP2 Protein
- KIP2 Protein, p57
- p57KIP2 Protein
- Cyclin-Dependent Kinase Inhibitor 1C
- Cyclin Dependent Kinase Inhibitor 1C
- Cyclin Kinase Inhibitor Protein 2
- CDKN1C Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p57".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p57".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p57" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p57" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2008 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2012 | 3 | 4 | 7 |
| 2013 | 1 | 2 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p57" by people in Profiles.
-
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023 10; 37(10):2094-2106.
-
DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency. Am J Hum Genet. 2018 12 06; 103(6):1038-1044.
-
ORAI1 Activates Proliferation of Lymphatic Endothelial Cells in Response to Laminar Flow Through Kr?ppel-Like Factors 2 and 4. Circ Res. 2017 Apr 28; 120(9):1426-1439.
-
TGF-?/?2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest. 2016 Feb; 126(2):527-42.
-
Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis. Hepatology. 2016 Mar; 63(3):898-913.
-
Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18. Development. 2013 Sep; 140(18):3809-18.
-
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle. 2013 Mar 15; 12(6):935-43.
-
Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
-
Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists. Am J Surg Pathol. 2012 Dec; 36(12):1747-60.
-
CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle. 2012 Dec 15; 11(24):4633-41.